Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 292 for:    ASPIRIN AND clopidogrel AND dual

Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02433587
Recruitment Status : Not yet recruiting
First Posted : May 5, 2015
Last Update Posted : June 16, 2016
Sponsor:
Information provided by (Responsible Party):
Dr. Vikram S. Kashyap, M.D., University Hospitals Cleveland Medical Center

Brief Summary:
The primary objective of the trial is to evaluate short versus long duration dual antiplatelet therapy in patients undergoing lower extremity endovascular revascularization.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Endovascular Procedures Drug: Aspirin Drug: Clopidogrel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization
Study Start Date : July 2016
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Short Term
The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
Drug: Aspirin
Drug: Clopidogrel
Experimental: Long Term
The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
Drug: Aspirin
Drug: Clopidogrel



Primary Outcome Measures :
  1. Major Adverse Cardiovascular Event Rates [ Time Frame: 12 months post-intervention ]
  2. Major Adverse Limb Event Rates [ Time Frame: 12 months post-intervention ]

Secondary Outcome Measures :
  1. Quality of Life [ Time Frame: 12 Months post-intervention ]
    Assessed by Intermittent Claudication Questionnaire and Short Form-36 Health Survey



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide signed informed consent before initiation of any study related procedures
  2. Be at least 18 years of age
  3. Successful percutaneous lower extremity (iliac and infrainguinal) endovascular revascularization (percutaneous transluminal angioplasty, and /or stent).
  4. At least 1 vessel run-off in segment distal to the intervention
  5. Rutherford Classification 2-5 that is unresponsive to medical therapy

Exclusion Criteria:

  1. Acute limb ischemia
  2. Procedure includes device deployment that has specific FDA regulations for anticoagulation/anti-platelet medication regimen.
  3. Patient undergoing atherectomy procedure
  4. Intervention includes deployment of drug eluted stent
  5. Critical limb ischemia (Rutherford Classification 6)
  6. Thrombocytopenia: Platelet count <50k
  7. Liver disease (Childs-Pugh B or C)
  8. Existing need for on going clopidogrel therapy
  9. Proton Pump Inhibitor Use (If unable to be switched)
  10. Need for therapeutic anticoagulation
  11. Known hypercoagulable disorder
  12. Allergy or contraindication to aspirin or clopidogrel
  13. Pregnancy
  14. Patients enrolled in another investigational drug or device study within the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02433587


Contacts
Layout table for location contacts
Contact: Vikram Kashyap, MD 216-844-3013 vikram.kashyap@uhhospitals.org
Contact: Andrew Shevitz, MA 216-844-7532

Locations
Layout table for location information
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Vikram Kashyap, MD    216-844-7532    vikram.kashyap@uhhospitals.org   
Sponsors and Collaborators
University Hospitals Cleveland Medical Center

Layout table for additonal information
Responsible Party: Dr. Vikram S. Kashyap, M.D., Chief, Division of Vascular Surgery & Endovascular Therapy, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier: NCT02433587     History of Changes
Other Study ID Numbers: 08-14-29
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: June 16, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Clopidogrel
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents